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ABSTRACT
Background
Surrogate markers of protective immunity to malaria in humans are needed to rationalize
malaria vaccine discovery and development. In an effort to identify such markers, and thereby
provide a clue to the complex equation malaria vaccine development is facing, we investigated
the relationship between protection acquired through exposure in the field with naturally
occurring immune responses (i.e., induced by the parasite) to molecules that are considered as
valuable vaccine candidates.
Methods and Findings
We analyzed, under comparative conditions, the antibody responses of each of six isotypes
to five leading malaria vaccine candidates in relation to protection acquired by exposure to
natural challenges in 217 of the 247 inhabitants of the African village of Dielmo, Senegal (96
children and 121 older adolescents and adults). The status of susceptibility or resistance to
malaria was determined by active case detection performed daily by medical doctors over 6 y
from a unique follow-up study of this village. Of the 30 immune responses measured, only one,
antibodies of the IgG3 isotype directed to merozoite surface protein 3 (MSP3), was strongly
associated with clinical protection against malaria in all age groups, i.e., independently of age.
This immunological parameter had a higher statistical significance than the sickle cell trait, the
strongest factor of protection known against Plasmodium falciparum. A single determination of
antibody was significantly associated with the clinical outcome over six consecutive years in
children submitted to massive natural parasite challenges by mosquitoes (over three parasite
inoculations per week). Finally, the target epitopes of these antibodies were found to be fully
conserved.
Conclusions
Since anti-MSP3 IgG3 antibodies can naturally develop along with protection against P.
falciparum infection in young children, our results provide the encouraging indication that
these antibodies should be possible to elicit by vaccination early in life. Since these antibodies
have been found to achieve parasite killing under in vitro and in vivo conditions, and since they
can be readily elicited by immunisation in naı ¨ve volunteers, our immunoepidemiological
findings support the further development of MSP3-based vaccine formulations.
The Editors’ Summary of this article follows the references.
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A malaria vaccine is urgently needed [1,2]; however, the
rational development of such a vaccine has suffered from a
lack of knowledge of the relevance of experimental models
[3]. This has resulted in a highly unsatisfactory situation in
which each hypothesis derived from such models is inves-
tigated in lengthy and costly clinical trials. The lack of a
reliable surrogate marker of protection in humans is thus a
recognized limitation to the identiﬁcation and development
of efﬁcacious vaccines [4].
The role of antibodies in clinical protection against malaria
erythrocytic stages has long been recognized by in vivo
transfer of antibodies from protected African adults to
nonprotected individuals infected with P. falciparum [5,6].
However, several decades later it remains unclear which of
the many antibody speciﬁcities contained in such sera may
play a critical role, and hence which of the corresponding
antigen(s) may represent potential vaccine candidate(s).
Identiﬁcation of such antigens requires the characterization
of antibody species in relation to the precisely deﬁned
medical status of individuals exposed under ﬁeld conditions,
and in a longitudinal manner, since malaria attacks are
spread over time. The corresponding epidemiological con-
ditions were therefore established in an area of Senegal so as
to fulﬁl two main features: (i) to include active case detection,
i.e., by daily medical visits to each individual over several
years and by providing access to medical care 24 h a day, (ii)
making use of improved diagnostic criteria in order to
distinguish malaria from other fevers, namely the pyrogenic
threshold of parasite density as deﬁned in this particular area
[7], the validity of which was conﬁrmed independently [8,9].
Employing these criteria represents a substantial improve-
ment in the assessment of bona ﬁde clinical malaria episodes
since, as shown below, both refractory and susceptible
individuals can be accurately identiﬁed using these criteria
in all age groups.
Most immunoclinical studies have dealt with a single
antigen in a given location, precluding any comparative
assessment of the relevance of each antigen. The aim of the
present study was to correlate clinical protection in an
endemic population with the immune response to ﬁve
leading malarial vaccine candidates that are currently under-
way in, or about to enter, numerous clinical trials (see list of
trials at http://www.who.int/vaccine_research/documents/en/
malaria_table.pdf) [1]. Four of these molecules are the
targets of antibodies that inhibit red blood cell invasion,
namely merozoite surface protein 1 (MSP1) [10], MSP2 [11],
apical membrane antigen 1 (AMA1) [12,13], and ring-infected
erythrocyte surface antigen (RESA) [14], whereas MSP3 is
targeted by cytophilic antibodies inhibiting intra-erythro-
cytic parasite growth in a monocyte-dependent manner [15].
Methods
Study Area and Collection of Clinical Data
The village of Dielmo (138459N, 168259W) is localized in one
of the rare areas of Senegal, West Africa where malaria is
holoendemic (experiencing perennially a high level of trans-
mission by mosquitoes, due to the presence of a permanent
stream), with an average of 5.16 infective bites per week
during the ﬁrst 2 y of the survey [16]. The 247 inhabitants of
Dielmo village were enrolled in a prospective study using to
our knowledge one of the most stringent protocols of clinical
follow-up ever applied in the ﬁeld and consisting of daily
surveillance by medical staff (present 24 h/d, 7 d/wk) in order
to identify and to analyse all episodes of morbidity [16]. The
ﬁeld set-up was designed and tested over 1 y before the actual
study was conducted (e.g., questionnaires used for daily
surveillance were written in three languages, and the
reliability of responses were systematically addressed).
Each villager was visited daily at home and had the ability
to consult at any time one of the two medical doctors
permanently on-site. In the event of a report or complaint of
fever, headache, or vomiting, a medical examination and
three thick blood ﬁlms were made. One of the thick blood
smears was Giemsa-stained and examined immediately on-
site for the purpose of deciding on treatment. The other two
slides were dehaemoglobinized, stained, and examined in our
central laboratory in Dakar, using more rigorous and stand-
ardized conditions with quality control assessment [16]. The
results of the latter slides were used for the present study.
The criteria leading to a given episode of morbidity being
attributed to malaria have been studied in detail and deﬁned
previously [7]: a malaria attack was deﬁned as an episode of
fever (temperature .38.5 8C) associated with a parasite
density exceeding an age-dependent pyrogenic threshold
described for this village (the parasite density threshold for
each age group was determined to be 24,500 parasites/lla t
ages , 12 mo; 27,000 at 12–23 mo; 24,000 at 2 y; 20,000 at 5 y;
15,500 at 10 y; 10,000 at 20 y; 7,500 at 30 y; and 5,000 in adults
older than 40 y) [7]. The improved ability of this criterion to
distinguish malaria attacks from other causes of fever has
been documented [17] and has been further conﬁrmed
independently in different African settings [18–20].
Antimalarial treatment was initiated in all participants
with conﬁrmed malaria attack according to previously
established criteria [7,21]. During the study period, treatment
relied on the administration of quinine chlorhydrate (Quini-
max), chosen in view of its efﬁcacy in this area of chloroquine
resistance and its fast effect, given orally at a dose of 8 mg/kg
under medical supervision (with assessment of proper
ingestion) at 8 h intervals (i.e., 25 mg/kg/d) for 7 d. It is of
note that the very short half-life of quinine has the advantage
that it avoids a buildup of a prophylactic concentration of the
drug in the receivers’ blood that could provide artiﬁcial
protection in the following weeks or months, i.e., the
inﬂuence of this confounding factor is avoided. Since free
medical care was available 24 h/d, self-treatment was most
uncommon, as was ascertained by systematic detection of
antimalarial drugs previously [16].
All villagers were farmers with equivalent economic and
social status. Entomological studies were conducted 15 d/mo,
year-round, by 12 investigators rotating each night from one
household to another. These studies were conducted for
several years simultaneously with clinical data recording.
They did not show any substantial differences in exposure to
Anopheles from one house to the other, and clinical cases were
at similar prevalence in all households. The average entomo-
logical inoculation rates reported in this paper correspond to
the actual entomological inoculation rates measured during
the same years of the clinical survey.
The Dielmo Project was initiated in 1990, and the present
study initially focussed on the period from July 1990 to July
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individual received an average of 520 P. falciparum-infected
bites. The serum samples were collected in a cross-sectional
study in May and June 1991. The clinical data collected from
July 1990 to July 1991 were used for retrospective statistical
analysis, and the clinical data collected between July 1991 and
July 1992 were used for prospective statistical studies. Since
the village continued to be followed up clinically according to
the same criteria, and in view of results obtained from July
1990 to July 1992, clinical data obtained over the ensuing 5 y
(up to July 1997) were employed for the long-term analysis.
Ethical Approval
The informed consent of each villager (or that of the
parents in the case of children) was obtained at the beginning
of the study after a thorough explanation of its purpose and
was renewed at the beginning of each year of the survey. The
study design received clearance from the Senegal National
Ethics Committee (Dakar, Senegal).
Antigens
The peptide MSP3-b used in this study is part of the C-
terminal domain of the MSP3 DG210 protein and has been
described previously [22,23]. It is located in the highly
conserved C-terminal region of the molecule (amino acids
185–254) [24,25] (Oeuvray et al., unpublished data). It deﬁnes
a B cell epitope targeted by naturally occurring antibodies.
Human afﬁnity-puriﬁed antibodies on peptide MSP3-b react
with the parasite native protein in Western blots of P.
falciparum schizont extracts, and in immunoﬂuorescence on
infected RBCs, thus showing the relevance of the peptide
epitope to the original protein, and inhibit parasite growth in
cooperation with blood monocytes, in vitro or in vivo, in
passive transfer experiments [24,25]. The RESA peptide was
purchased from Bachem (Bubendorf, Switzerland). The same
sera were tested under the same experimental conditions
using the MSP1–19 [26,27] and two MSP2 (fcr3 and 3d7 alleles)
polypeptides expressed in E. coli [28], and under the super-
vision of David Narum (Biomedical Primate Research Center,
The Netherlands), using the AMA-1 recombinant protein,
derived from clone 7G8 sequence, expressed in baculovirus,
and hence properly conformed [27] (a gift of D. Narum and A.
Thomas (Biomedical Primate Research Center, The Nether-
lands), ). Control peptides and recombinant proteins were
chosen among pre-erythrocyte stage antigens, namely the
peptides LSA1-R derived from liver stage antigen 1 [29], and
LSA3-RE derived from liver stage antigen 3 [30], and the
recombinant R32 LR derived from the circumsporozoite (CS)
protein [31] spanning the NANP repeats.
ELISAs
The total and isotype-speciﬁc ELISAs were performed as
described previously [22,32,33] using secondary monoclonal
antibodies originally selected as reacting faithfully with
subclass allotypes of European, African, and Asian origins
[22,32,33]. For IgG1 to IgG4 (IgG1–4), monoclonal mouse
anti-human subclasses (clones NL16 ¼ IgG1 [Boehringer],
HP6002 ¼ IgG2 [Sigma], Zg4 ¼ IgG3, and RJ4 ¼ IgG4 [both
from Immunotech]) were used, at a ﬁnal dilution of 1:2,000;
1:10,000; 1:10,000; and 1:1,000 respectively. For IgM (clone
M11) determinations, the ﬁnal dilution was 1:15,000. Each
dilution of each monoclonal antibody had been previously
determined as speciﬁcally reacting with the corresponding
human isotype without showing signiﬁcant cross-reaction
with other isotypes [22,32,33].
All ELISA determinations were performed on coded serum
samples, in a blinded manner—i.e., the investigators were not
aware of the morbidity data of the corresponding patients.
The results were expressed ﬁrst as ratios of OD values (or
arbitrary units) as previously described [22,32,33] which were
then used to estimate immunoglobulin concentrations. To
calculate the OD ratios, each ELISA plate included sera from
seven healthy French non-malaria-exposed blood donors,
chosen as being representative of results obtained previously
using sera from 200 French blood donors without exposure to
malaria, i.e., yielding the same mean OD 6 standard deviation
(SD) value. The OD values corresponding to background
responses from blood donors never exposed to malaria
calculated in this manner were usually low, eg for MSP3:
0.035 (for IgG1); 0.050 (for IgG2); 0.027 (for IgG3); 0.031 (for
IgG4); and 0.112 (for IgM). However, the precise cut-off value
was calculated for each ELISA plate using the OD values
recorded using the seven negative control sera included in
e a c hp l a t e .T h es a m ep o s i t i v ea n dn e g a t i v es e r aw e r e
systematically included in each 96 wells ELISA plate
throughout the entire study. For the evaluation of immuno-
globulin concentrations, the CLB reference serum with
known amounts of each IgG subclass, IgM, and IgA (Central
Laboratory of the Netherlands Red Cross blood transfusion
service, Amsterdam, The Netherlands), and human reagents
(either IgG myelomas or puriﬁed human IgM from Sigma)
were used. The OD values obtained with our secondary
monoclonal antibodies over a range of dilutions of the
different reagents were used to determine the actual amounts
of each immunoglobulin speciﬁc for each antigen present,
and were converted to lg/ml equivalents.
Analysis of Sequence Polymorphism in the msp3 Gene
MSP3 PCR and sequencing focussed on the original DG 210
clone sequence corresponding to the C-terminal domain
containing the three B cell epitope regions a, b, and c, as well
as three T helper cell epitopes [23]. Forty-ﬁve P. falciparum
isolates and strains were studied, obtained as follows: (i) ten
from Kanbauk, Myanmar, Southeast Asia, where transmission
is seasonal with between two and ten infective bites per year;
(ii) 15 from Dielmo, Senegal, where transmission is holoen-
demic with 200 infective bites per year [16]; iii) ten from
Ariquemes, State of Rondo ˆnia, Brazil, where transmission is
perennial with 6.6 infective bites per month, and (iv) 13
laboratory strains—four from Tanzania, one from either
Uganda, Liberia, Senegal, Thailand, Myanmar, Papua New
Guinea, India, Brazil or Honduras and two from South East
Asia. Parasite DNA from P. falciparum laboratory strains was
extracted as described earlier [34]. DNA was extracted from
blood samples using the QIAamp Blood Kit (Qiagen) in
accordance with the manufacturer’s instructions.
PCR and sequencing on parasite DNA was performed with
primers DA151 (59-G CCG GAA TTC CAT GAA AGG GCA
AAA AAT GCT TA-39) (nucleotides 562 to 585) (EcoRI
cleavage site underlined) and DA152 (59-G CCG GGA TCC
ATT TTC CTT AGA TAT ATT TTC C-39) (nucleotides 770 to
748) (BamHI cleavage site underlined). The program for PCR
was a denaturation step at 94 8C for 1 min, an annealing step
at 65 8C for 1 min followed by an extension step at 72 8C for 2
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GeneAmp PCR Kit (Perkin Elmer). The ampliﬁed products
were puriﬁed by Spin-X (Costar) before sequencing on the
ABI PRISM 373A DNA Sequencer using the ABI PRISM Dye
Terminator Cycle Sequencing Ready Reaction Kit (Perkin
Elmer). Nucleotide sequences were aligned by the CLUSTAL
V program.
Statistical Analysis
Data from 217 of the 247 Dielmo inhabitants were used,
corresponding to those from whom serum samples had been
collected. Thirty individuals, mostly adults, were excluded
from the 247 because they spent less than half of their time in
Dielmo during the follow-up, and were therefore deemed
unsuitable for inclusion given that the degree of exposure
plays a crucial role in the development and persistence of
protective immunity. Of note, women who were pregnant for
more than 10% of the study period were not included in the
analysis and will be the subject of a separate report. A period
of two years—one year before and one year after the serum
sampling—was chosen for the initial clinical analysis, during
which the number of malaria attacks was recorded. The
villagers who were tested during a longer period of time, i.e.,
up to 6 y, corresponded to a subset of children and adults
who stayed for more than 75% of their life in the village. The
time spent in the village was determined on a continuous,
active, and daily survey carried out by the medical team.
Information pertaining to the IgG1, IgG2, IgG3, IgG4, IgM,
and IgA antibodies to MSP3, MSP1, MSP2 (FCR3), MSP2
(3D7), AMA1, and RESA; and IgG and IgM levels to LSA1-R,
LSA3-RE, CS protein (R32LR recombinant protein), were
thus available, as well as age, sex, number of days spent in the
village, G6PD proﬁle, and haemoglobin AS phenotype.
An inspection of the number of malaria attacks (identiﬁed
over 2 y) plotted against the age of the individual affected,
showed that they were not linearly distributed. A maximum-
likelihood method was developed for adjustment of the data
corresponding to malaria attacks. A nonlinear model was
ﬁtted to using a negative binomial loss function to calculate
the breakpoint of threshold of age-dependent acquisition of
immunity, for men and women separately in a manner similar
to that described by Kocherlakota and Kocherlakota [35]
(developed by K. Dietz, Department of Biomedical Biometry,
University Eberhard-Karls of Tu ¨bingen, Tu ¨bingen, Germany).
Even though a Poisson distribution also ﬁtted the data, in the
end a negative binomial was chosen, because it is frequently
used to describe this type of data. Further assumptions were
that every individual has a speciﬁc risk for a malaria attack.
The distribution for the risk is, as conventionally used, a
gamma distribution. The gamma distribution was stand-
ardized and had a mean of 1. The bivariate negative binomial
distribution for both years had three parameters: a term for
the variances (1/k) for the gamma distribution and the mean
values for the two different years. The real risk of malaria in
the different year is multiplicatory—and was given by a
product term that consisted of an individual term and a year
speciﬁc term, the latter being the same for all individuals. It
was assumed that, for a particular individual, the number of
attacks in the subsequent years was independently distributed
according to a Poisson distribution with different means,
which were proportional to the individual exposure risk.
The statistical models used for analysis of data were
multivariate models. The potential relationship between
malaria attacks (the variable to explain) and selected
explanatory variables was tested using a log (1 þ x) trans-
formation of the number of attacks. The explanatory
variables were selected on the basis of our existing knowledge
of the potential involvement of these different parameters
(with reference to our previous observations in different
malaria-endemic areas). Age and age
2, sex, haemoglobin
phenotype and G6PD deﬁcit as well as the individual
immunoglobulin isotypes (i.e., IgG1, IgG2, IgG3, and IgG4)
that were available and suspected of having a potential
impact on the dependent variable (the number of malaria
attacks), were tested in backward stepwise regression,
eliminating, by hand, the variables which were not signiﬁcant.
The criterion for inclusion or elimination of the explanatory
variables was that a predictor variable was included when its
partial regression coefﬁcient was signiﬁcant at the 0.05 level
and eliminated when its partial regression coefﬁcient failed
to be signiﬁcant at the 0.1 level. The assumption that the
regression equation accurately summarized the data was
visually veriﬁed by examination of the residuals plotted
against the ﬁtted values. The signiﬁcant terms were retained
for further analysis and retested again to avoid exclusion due
to interactions.
A negative binomial distribution is conventionally accep-
ted for most disease data and has therefore been used to test
the signiﬁcant variables. Nominal and ordinal logistic
regression (with no attack, one malaria attack, and two
malaria attacks for the adults) and multivariate regression
using a negative binomial distribution were used to analyse
data with JMP software (SAS Institute, Cary, NC). For this
analysis, IgG1 to IgG4 values were log-transformed or
dichotomised as indicated in the ELISA section. A nonlinear
model was also ﬁtted to the signiﬁcant variables of interest
used to establish indications of long-term protection (be-
tween 1 and 6 y after the blood samples were tested) in
children and adults of Dielmo. Chi-square and signiﬁcance
values were calculated looking at the difference between the
full model and the model without the respective term. We
used a level of signiﬁcance of 0.05.
Results
Characterization of the Study Population
Of the 247 individuals constituting the whole village
population of Dielmo, 217 were enrolled for the present
study. The study cohort included 102 females (mean age 6 SD
25.9 6 21.1 y) and 115 males (21.9 6 18.5 y). During the year
preceding the blood sampling, the inhabitants of Dielmo
involved in this study were present in the village during
78.2% 6 27.6% of the time (95% conﬁdence interval [CI]
74.5%–82.0%). At the time of blood sampling, 112 inhab-
itants (mean age 6 SD 30.5 6 18.2 y) had a negative thick
smear, whereas blood parasitaemia was detected in 55
individuals (21.8 6 16.6 y) with less than 5,000 parasites/ll,
and in 50 individuals (10.6 6 10.7 y) who had   5,000
parasites/ll. In total, 130 villagers (30.8 6 18.2 y) never
presented with a malaria attack during the 2 y of follow-up
and had a mean parasitaemia of 3,251 6 10,841 parasites/ll
(95% CI 1,553–4,949) at the time of sampling, whereas 87
(mean age 6 SD 14.4 6 18.3 y) had at least one malaria attack
with a mean parasitaemia of 41,814 6 191,964 parasites/ll
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phenotype was AA in 191 individuals, AS in 23, and AC in 3;
46 villagers had a G6PD deﬁcit.
Identification of Clinical Cases and Evidence of Rapidly
Acquired Protection in Young Children
The relevance of the analysis of immune responses
critically depends on the reliability of clinical data. The daily
clinical survey was satisfactorily carried out on 217 of the 247
individuals constituting the whole village population, who
showed a classical age-dependent acquisition of clinical and
parasitological immunity (Figure 1, shaded area). However, it
was possible to distinguish, among the children, a subset of 14
individuals (20.9%) who did not present with an attack of
malaria during the 2 y of follow-up (4/35 and 10/32 in the 0–5
y and 6–10 y age groups, respectively). Conversely, the study
design also led to the identiﬁcation of a small subset of 14
adolescents and adults (10.8%) occasionally susceptible to
malaria attacks (3/28 and 11/101 in the 15–20 y and .21 y age
groups, respectively), though the majority had acquired
protection. However, in adults, symptoms were of short
duration and resolved spontaneously, i.e., without requiring
treatment in most cases [7,16,36].
The existence of such rapidly acquired protection in very
young children and, conversely, the occurrence of brief
malaria attacks in adults, have seldom been reported
previously, possibly due to the use of less-stringent surveil-
lance setups. The pattern of clinical incidence in Dielmo
remains similar to that described in other high-endemicity
African areas [37] with a far greater number of attacks in
younger individuals, e.g., 3.45 clinical attacks per year in
children aged 1–5 y versus 0.1 attack per year in adults.
Nevertheless, the daily surveillance of highly exposed villagers
made it possible to distinguish in every age group individuals
with or without malaria attacks who can therefore be referred
to below as ‘‘nonprotected’’ and ‘‘protected,’’ respectively, for
the duration of the 2 y follow-up period. The monthly surveys
of entomological inoculations, conducted during the clinical
follow-up period, showed a very high level of transmission,
with an estimate of 260 infective mosquito bites per person
per year, i.e., 520 parasite inoculations over the 2 y survey,
with little house to house variation, leading us to exclude the
hypothesis that villagers without malaria attacks were not
exposed.
This clinical situation was in most instances stable since
only 13% of participants changed clinical status from the ﬁrst
to the second year of follow-up. The cases recorded are
therefore well suited to the identiﬁcation of immune
correlates of protection and, furthermore, for the ﬁrst time
this analysis can be performed in an age-independent
manner.
Cytophilic Anti-MSP3 Antibodies Correlate with Clinical
Immunity
The overall prevalence of IgG and IgM antibodies against
the MSP3-b epitope in the 217 individuals studied was high
(97.2% and 93.1%, respectively), whereas the prevalence of
IgA was low (19.3%). MSP3-speciﬁc IgE antibodies could not
be detected (unpublished data). Among the IgGs, the two
cytophilic classes, IgG1 and IgG3, were the most abundant
(Figure 1) and they both increased as a function of age,
whereas the increase was modest for IgG2 and IgM antibodies,
and low for IgG4 antibodies in all age groups.
Responses to other malaria antigens, including MSP1,
MSP2-FC27, MSP2-3D7, RESA, and AMA-1, were also found
to increase with age in this study (unpublished data) as has
been observed in previous studies [38–42]. Therefore, due to
this age-dependent increase, all antibodies measured showed
an overall inverse relationship with the prevalence of clinical
attacks (Figure 1, shaded area), a phenomenon reported in
most previous studies in African settings and sometimes
taken as indicating that protection is afforded by those
antibodies [33,38,43–45]. The prevalence of responses to pre-
erythrocytic antigens, such as CS, LSA1, and LSA3, also
Figure 1. Means and Standard Deviations of Anti-MSP3-b IgG1, IgG2, IgG3, IgG4, and IgM Antibody Responses per Age Group
Concentrations of antibodies are estimated as described in the Methods section. For each age group the mean number of malaria attacks recorded
during the first year of follow-up is indicated by the shaded area. The numbers of individuals in each age group were: 5 (0–1 y), 14 (2–3 y), 17 (4–5 y), 14
(6–7 y), 12 (8–9 y), 13 (10–11 y), 11 (12–14 y), 18 (15–18 y), 13 19–21 y), 100 (.21 y), respectively.
doi:10.1371/journal.pmed.0040320.g001
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degree of exposure to infected mosquitoes (see Figure S1).
Antibodies against the pre-erythrocytic antigens were not
included in the present statistical analysis.
We ﬁrst sought by stepwise regression analysis if it was
possible to select a subset of antibody responses that would
tend to predict the number of malaria attacks when
controlling for age. We then examined the predictive value
in terms of clinical protection of a positive antibody response
for each IgG isotype, to each of the ﬁve molecules studied, for
both each year separately and combined. A highly consistent
association was observed between protection and anti-MSP3
IgG3 antibodies for each of the years studied, as well as for
the two years combined, and this indication persisted even
when controlling for age (age-adjusted odds ratio [OR] and
95% CI¼7.19 [2.70–22.85], p , 0.001 for the 2 y of follow-up),
whereas no similar association was found, when age was
accounted for, for any of the other isotypes, nor for any of the
various antibody responses to the other vaccine candidates
(see Table S1). For example, for 2 y of survey, age-adjusted
ORs and 95% CIs were, for anti-MSP1 IgG1, 0.36 (0.076–
12.36), p ¼ 0.134; for anti-MSP-1 IgG3, 1.38 (0.60–3.15), p ¼
0.437; for anti-AMA1 IgG3, 1.01 (0.41–2.40), p ¼ 0.975; for
anti-RESA IgG3, 1.18 (0.59–2.35), p ¼ 0.637; for anti-MSP2
(FC27) IgG3, 0.74 (0.135–3.952), p ¼ 0.727; and for anti-MSP2
(3D7), 0.81 (0.13–49), p ¼ 0.823. The protected group had
mean anti-MSP3 IgG3 values 3.75 times and 4.3 times higher
than individuals having experienced either one or two or
more attacks, respectively. The malaria attacks recorded over
2 y among the 177 individuals with anti-MSP3 IgG3 were 2.52-
fold less frequent than among the 40 participants without
detectable anti-MSP3 IgG3 responses.
We have reported that it is the relative proportion of
cytophilic antibodies to noncytophilic antibodies (the C:NC
ratio) that is the most important surrogate marker of
protection to date [32,46]. This is because anti-MSP3 anti-
bodies act in a monocyte-dependent manner, requiring
binding to Fc-c receptors on monocytes [6,32]. The C:NC
ratio takes into account the possible, and demonstrated,
competition of noncytophilic antibodies directed towards the
same epitope [15,32]. We found a consistently higher C:NC
ratio, that is, a quantitative dominance of cytophilic classes,
among protected as compared to nonprotected participants.
This higher ratio was found in each age group (Figure 2),
though it reached statistical signiﬁcance only in the two
youngest and the oldest age groups (0–5 y, p , 0.01; 6–10 y, p
, 0.03; and .20, p , 0.007), probably due to group size. The
overall C:NC ratio was signiﬁcantly associated with protec-
tion for each year studied (OR [95% CI]¼2.79 [1.50–5.22], p¼
0.001 for the year before sampling and 2.82 [1.51–5.30], p ¼
0.0012 for the year following the sampling), and for the two
years combined (age-adjusted OR [95% CI] ¼ 3.34 [1.72 –
6.67], p , 0.001). For the 2 y of survey, the other parameters
were not signiﬁcant, e.g., age-adjusted ORs (95% CIs) for the
C:NC ratios were, for MSP1, 1.08 (0.57–2.11), p ¼ 0.81; for
AMA-1, 0.83 (0.43–1.61), p¼0.598; for RESA, 0.54 (0.13–2.04),
p¼0.387; for MSP2 (FC27), 1.20 (0.43–3.38), p¼0.723; and for
MSP2 (3D7), 1.35 (0.50–2.33), p ¼ 0.551.
IgG3 Anti-MSP3 Antibodies Are Strongly Associated with
Clinical Protection against Malaria
Improved statistical analyses necessitated the use of larger
group sizes. Since there was a clear age-dependent decrease
in the number of attacks in children, whereas in adults the
number of attacks was no longer age-dependent, we next
determined the age threshold that informed the separation of
individuals into two groups according to this criterion: for
women this was 13.4 y and for men 17.9 y, over the 2 y
observation period. These two groups were thus analysed in
detail separately.
Among the 121 individuals of the ‘‘adults’’ group, analyses
of data by ordinal logistic regression showed that only MSP3
IgG3 and the C:NC ratio of MSP3 were associated with
protection, i.e., negatively correlated with the number of
malaria attacks (L-R Chi-square ¼ 6.91; p ¼ 0.0086 and L-R
Chi-square ¼ 10.84; p ¼ 0.001 respectively). MSP1 IgG4 and
AMA1 IgG3 were marginally signiﬁcant if tested separately (p
¼ 0.04 and 0.05 respectively), but were not signiﬁcant if
included in a model with MSP3 IgG3. No other variable
showed any signiﬁcance (unpublished data). In a nominal
logistic regression, for MSP3 IgG3 the OR (95% CI) was 23.7
(3.15–238.36); and for the C:NC MSP3 ratio, it was 71.48 (3.65–
1,339.68). The ORs for all other isotypes and other molecules
did not reach signiﬁcance. When the results were dichotom-
ised, only MSP3 IgG3 (p ¼ 0.022) and the C:NC ratio of MSP3
(p ¼ 0.01) showed a signiﬁcant relationship with protection.
The surrogate value of anti-MSP3 IgG3 is graphically
indicated in Figure 3, in which the risk of occurrence of
one or two or more malaria attacks is shown to decrease in
adults when the anti-MSP3 IgG3 levels increase.
Among the 96 individuals included in the ‘‘children’’
group, all variables were tested in a backward stepwise
Figure 2. Ratios of Cytophilic to Noncytophilic Anti-MSP3 Responses
Found Among Protected and Nonprotected Individuals of Dielmo
The mean ratios of (IgG1 þ IgG3) to (IgG2þ IgG4þ IgM) antibody
responses (i.e., the cytophilic to noncytophilic [C:NC] ratios) were
calculated for protected (open circles) and unprotected individuals
(closed circles) within each age group. Error bars indicate the SD
calculated for each age group. The number of individuals within each
group is indicated in parentheses. A protected person is defined as an
individual in whom no malaria attack was recorded during the first year
of follow-up.
doi:10.1371/journal.pmed.0040320.g002
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tions and then a negative binomial model ﬁtted to the
signiﬁcant variables. The ﬁnal model contained: (i) For IgG3:
age (v
2¼55.46, p , 0.001), MSP3 IgG3, (v
2¼14.30; p , 0.001)
and haemoglobin AS phenotype (v
2 ¼ 5.56, p ¼ 0.018), or (ii)
For C:NC ratio: age (v
2 ¼ 67.51; p , 0.001), MSP3 C:NC (v
2 ¼
12.21; p , 0.001), and haemoglobin AS phenotype (v
2¼7.39; p
¼ 0.0066). No other variable was found to be signiﬁcant. For
dichotomous antibody concentrations, MSP3 IgG3 (v
2 ¼7.46,
p ¼ 0.0063) and MSP3 C:CN (v
2 ¼ 4.036, p ¼ 0.045) were also
signiﬁcant. The OR (95% CI), when tested in a nominal
logistic regression model, was for age, 51.15 (6.71–515.37), p ,
0.001; and for MSP3 IgG3, 15.49 (1.57–184.65), p¼0.0219 (for
age 96.93 [12.16–1093.25], p , 0.001 and for MSP3 C:NC 64.19
[2.94–2,204.40], p ¼ 0.0118). Results from an ordinal regres-
sion model with no attack, one, or more than one attack were
similar to the results from the previous model except that
haemoglobin AS phenotype was no longer signiﬁcant.
The Clinical Significance of IgG3 Anti-MSP3 Antibodies
Extends to Several Years
In view of the above results, which show a strong association
of the surrogate marker with clinical protection, and since
individuals in the village were followed up clinically in the
ensuing years, we next addressed the question of the long-
term clinical signiﬁcance of a single antibody determination.
Individuals resident in Dielmo for more than 75% of the
time in the ensuing 6 y after the initial blood sampling were
selected for this analysis. For this reason, the number of
individuals included in the 6 y analysis is lower than in the 2 y
analysis.
In the adult group, the association of the IgG3 anti-MSP3
responses with protection was signiﬁcant for the year following
sampling (OR 14.1, p ¼ 0.019) but no longer signiﬁcant, in the
ensuing years (as shown in Table S2). This indication was not
found for anti-MSP1 IgG3, with OR (95% CI) of 7.27 (0.85–
145.35), p ¼ 0.111; for anti-AMA1 IgG3, 2.92 (0.19–303.21), p ¼
0.527; for anti-RESA IgG3, 2.67 (0.68–10.62), p ¼ 0.157; nor for
anti-MSP2 (FC27) IgG3, 0.78 (0.04–6.16), p ¼ 0.832.
In contrast, in the children group, a signiﬁcant association
of IgG3 anti-MSP-3 antibodies with clinical protection was
observed in the following 12, 24, and 36 mo of follow-up
(respective ORs 56.1, p ¼ 0.0063; 34.8, p ¼ 0.01, and 31.7, p ¼
0.009). Only by year 4 and onwards did the clinical value
decrease, though it remained signiﬁcant (OR, 15.49, p¼0.037;
18.2, p ¼ 0.031, and 21, p ¼ 0.036 on years 4, 5, and 6,
respectively, as shown in Table S2). Of note, a similar analysis
did not lead to the same observations for antibodies speciﬁc
to other antigens (for example, after 1 y of follow-up, it was
found in the children group, for anti-MSP1 IgG3, 1.30 [0.11–
29.67], p¼0.84; for anti-AMA1 IgG3, 0.93 [0.18–4.9], p¼0.931;
for anti-RESA IgG3, 1.89 [0.52–7.75], p¼0.345; for anti-MSP2
(FC27) IgG3, 0.20 [0.015–1.918], p ¼ 0.183; and for anti-MSP2
(3D7), 0.71 [0.05–9.14], p ¼ 0.785).
The above results were conﬁrmed using a nonlinear model
ﬁtted to the variables demonstrated to be signiﬁcant in the
previous analysis, i.e., age, haemoglobin AS phenotype, and
anti-MSP-3 IgG3. The maximum difference between the
mean number of malaria attacks identiﬁed in children with
anti-MSP-3 IgG3, and children without such a response (4.3-
fold), was detected 3 y after sampling (v
2 ¼ 11.76; p ¼ 0.0006)
and remained marked by year 4 of the study (v
2 ¼ 9.76; p ¼
0.0017). The differential number of attacks was still signiﬁ-
cant by year 6 of the follow-up (v
2¼4.64; p¼0.031) when the
model was compared with and without the antibody response.
Hence, the two methods of analysis provided convergent
conclusions indicative of the long-term clinical signiﬁcance
of a single IgG3 anti-MSP3b determination, in terms of the
resistance of children to malaria attacks.
Results are graphically illustrated in Figure 4, which shows
the cumulative number of malaria attacks over 6 y of follow-
up in Dielmo, in relation to IgG3 antibodies to each antigen.
When the analysis was performed comparing the same
individuals with either ‘‘low’’ or ‘‘high’’ antibody levels
(IgG3 levels below or above the median), similar conclusions
were reached (see Figure S2).
The Target Epitope of Antibodies Associated with
Protection Is Fully Conserved in Various Parasite Isolates
Since MSP3 appeared at this point to be a strong surrogate
marker of clinical protection, we deemed it important to
investigate whether this antigen exhibits the polymorphisms
reported for many malarial vaccine candidates [47–50]. The
sequence of the C terminus part of the gene, encoding three
B cell and four Th cell epitopes [23] was analyzed in 45
parasite strains and isolates and did not reveal any poly-
morphism, either at the amino acid level or at the nucleotide
level (unpublished data). The importance of this result is
supported by the parallel study of the nonrepetitive 39 region
of the CS gene (nucleotides 1,015 to 1,254), which revealed 16
nucleotide substitutions in the same 45 strains (ten within the
Th2R and six within the Th3R regions), all resulting in amino
acid substitutions, in agreement with previous reports [51].
Discussion
A detailed analysis of the malarial clinical status, based on
daily medical records actively collected from each inhabitant
Figure 3. The Probability of No, One, or Two Malaria Attacks in the
Adults of Dielmo as a Function of the Level of Anti-MSP3 IgG3 Responses
The chance of no attack increased markedly and almost reached a
maximum in parallel with the gradual increase in anti-MSP3b IgG3
responses. The probability that one or two malaria attacks occurred in
adults decreased as the anti-MSP3b IgG3 responses increased.
doi:10.1371/journal.pmed.0040320.g003
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relationship between clinical protection acquired through
natural exposure and the production of cytophilic anti-MSP-
3 antibodies, notably IgG3. The stronger relationship of this
marker with protection than that conferred by sickle cell trait
(i.e., S-type haemoglobin) indicates that its contribution to
the control of parasites is highly signiﬁcant and therefore
demonstrates its promise as a vaccine candidate. Above all,
the clinical value of this surrogate marker, i.e., its association
with protection, persisted out to six years in individuals who
are exposed to approximately 260 inoculations per year of
parasites by Anopheles mosquitoes [16].
Except for one study in which two antigens were
investigated in parallel [52], most immunoepidemiological
studies have addressed the surrogate value of antibodies only
to single vaccine candidates, each studied in distinct setups
and frequently with distinct criteria, thereby precluding
comparative analysis of the clinical signiﬁcance of immune
responses to each antigen. In the comparative analysis of ﬁve
antigens that we performed, the involvement of natural
antibody responses to the four other antigens studied
simultaneously did not reach signiﬁcance. In other words,
out of 30 different combinations of isotype-speciﬁc responses
determined for each of the inhabitants tested, only one was
strongly associated with naturally acquired protection. This
observation is of particular value, given the problem of
colinearity of immune responses, which could either hide this
relationship or bias the analysis towards the role of other
antibody responses. The other immune responses were not
associated with protection. This obviously does not mean that
they are not important, but that the conditions of our study
and the power of our analysis within the limitations of group
size cause the results to fail to reach signiﬁcance for these
other parameters.
In such epidemiological investigations, age is a confound-
ing factor, since protection builds up over time with
exposure, and hence with age [53,54]. This variable could be
fully controlled in our setup for the ﬁrst time as both
protected and nonprotected individuals were identiﬁed in
each age group by our study design. That some children can
rapidly acquire a potent and long-lasting level of protection
against the disease is a novel ﬁnding that has important
consequences: since protection induced by natural exposure
can develop early in life, it raises the realistic hope that it
should be feasible to induce protection at an early time point
by vaccination. The mechanisms leading to sustained pro-
tection over the years in some children remain hypothetical.
The strong association with protection of IgG3 responses in
younger individuals is reminiscent of similar ﬁndings made
Figure 4. Mean Cumulative Number of Malaria Attacks Identified over Six
Years of Follow-up in Dielmo, in Relation to IgG3 Antibodies to Each
Antigen
For each antigen, specific IgG3 responses were dichotomized (antibody
ratio less than or greater than 1) and in each group the occurrence of
malaria attacks was calculated. To avoid the confounding effect of age, a
subgroup of 49 children was selected for this analysis so that the mean
age was similar (5.5 6 2.6 y) among children with or without antibodies
to each antigen. The mean cumulative numbers of malaria attacks are
indicated for anti-MSP3b (A), anti-MSP1 (B), anti-AMA1 (C), and anti-
MSP2-3D7 (D) IgG3 responses with ratio values less than 1 (open circles)
or greater than 1 (closed circles). Error bars indicate SD.
doi:10.1371/journal.pmed.0040320.g004
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some children can achieve an early isotype switch towards
cytophilic responses, and thereby can remain free of malaria
attacks for extended periods of time.
Following the report that the isotype distribution of
antimalarial antibodies was a critical parameter of malaria
immunity [46], various studies conﬁrmed the increase of IgG3
with age, and hence with protection, for many malarial
antigens including SIRBC extract, MSP1, MSP2, AMA1, RESA,
GLURP, p126-SERP-SERA, EBA 175, TRAP, and Exp1
[28,38,39,45,52,55–62]. In these studies where, with few
exceptions [63], the children were collectively considered
nonprotected and the adults protected, the increase in
antibody levels with increasing age and increased protection
led to the report of an association between protection to
malaria and antibody to antigens including MSP1–19 [64],
MSP1 Block2 [65], SERP [57], and GLURP [56]. The absence of
any correlation between anti-MSP1–19 antibodies and pro-
tection demonstrated herein is in agreement with some [44]
but not all previous reports [66,67]. One study suggested that
the risk of malaria is reduced only when IgG antibodies to
MSP1–19 are present at very high titters [42]; however, more
recent work concluded that only antibodies inhibiting the
processing of MSP1, but not those directed to MSP1–19, were
associated with protection [42,68]. These processing-inhib-
itory antibodies were not investigated in our study. Responses
to the highly polymorphic MSP1-Block2 region have also
been reported to be associated with protection; however,
when corrected for age this effect was shown to be mainly
related to one of the 16 polymorphic constructs inducing low
titters of antibodies in a small subset of individuals. More-
over, responses waned over time and became negligible at the
end of the ﬁrst year, in contrast to antibodies to MSP3.
Recently it was reported that polymorphisms in the central
and N-terminal region of MSP3 appeared as a result of
immune selection. In that study, antibodies to both the
polymorphic region and the C terminus (which includes the
peptide MSP3b) were found to be signiﬁcantly associated with
naturally acquired protection [69]. Although only total IgG
was evaluated (and therefore the critical role of IgG3 could
not be identiﬁed) and the clinical data were collected over a
shorter period of 5 mo, this result is in agreement with our
current ﬁndings and supports the clinical value of anti-MSP3
Abs. Results reported elsewhere [69,58] also show that under
conditions of follow-up less stringent than in Dielmo, similar
conclusions were reached about the association of anti-MSP3
antibodies with protection and in other settings such as The
Gambia and Myanmar [69,58], i.e., with distinct human and
parasite genetic backgrounds, and much lower transmission
conditions.
The long-term clinical effect of a single anti-MSP3 anti-
body determination over a number of years in participants
that are receiving malaria inoculations by mosquitoes every
two days is impressive, particularly as it remained signiﬁcant
over six consecutive years. This ﬁnding has not been reported
for any other antigen, to our knowledge. The conceptual
importance and implications for vaccine development merit
further investigation in other settings. The longer-term
association in children than in adults is likely related to two
factors: (i) children can be divided into two groups, a small
subset acquiring protection early in life who remain
protected in the ensuing years (this is associated with our
surrogate marker) and the majority who do not, and (ii) most
adults are continuously protected against malaria, but some
may brieﬂy lose this protection and reacquire it after a short,
self-resolving attack. A long-term effect cannot be expected
in these occasional situations of brief loss of existing
protection.
Malaria vaccine discovery, which has relied for several
decades on preclinical in vitro and in vivo animal models, is
now increasingly reliant on clinical trials in humans. For two
major reasons this is driving vaccine development towards an
ever more unmanageable situation. One reason is that since
none of the preclinical models is recognised as being of
undisputable predictive value, each candidate must presently
be taken into lengthy, time-consuming and costly clinical
trials. From an initial number of 12 vaccine candidates, this
translates, with various antigen presentation systems, into 58
planned clinical trials (http://www.who.int/vaccine_research/
documents/en/malaria_table.pdf) and a concomitant in-
crease in development costs. The second reason is that the
elucidation of the malaria genome, although welcome, none-
theless generates knowledge about ;5,300 proteins—500-fold
more molecules than was previously known. These potential
antigens must now be assessed for their suitability for
inclusion in a malaria vaccine, a task that is not achievable
through individual vaccine efﬁcacy trials with each one.
The immunoepidemiological screening approach that we
have taken has the advantage of relying on immune responses
that occur in the ultimate target of a vaccine, namely human
beings. Hence, we postulate that this approach provides
results that are more relevant and ultimately more reliable
than those derived from any experimental model. It also has
the advantage of being rapid and applicable to any number of
antigens, with the sole drawback of not identifying antigens or
mechanisms that do not exist in nature. Our study indicates
that this method can point to major differences among
vaccine candidates when these are studied under comparative
conditions, and therefore provides one clue to the complex
equation malaria vaccine discovery is now facing.
The present study merely shows an association, i.e., value as
a surrogate marker, of anti-MSP3 antibodies with acquired
protection to malaria in exposed populations. However, this
immunoepidemiological result also agrees with results from a
series of experimental studies, conducted in vitro and in vivo,
that showed an antiparasitic effect of the same antibodies.
Human anti-MSP3b polyclonal [22,23,70,71] or monoclonal
antibodies [72,73], or animal anti-MSP3b antibodies [22,70],
were consistently found to exert a strong antiparasitic effect
in vitro with blood monocytes. It is noteworthy that the IgG3
version of a human recombinant antibody against MSP3b was
actually more effective in vitro than was the IgG1 version, and
that in the present independent immunoepidemiological
approach a greater association of the same isotype to the
same epitope is found [73]. Upon passive transfer in vivo in a
humanised mouse model, anti-MSP3b antibodies fully cleared
P. falciparum parasitaemia, using either naturally occurring or
vaccine-induced human antibodies [23,70,71]. Finally, vacci-
nation of primates with MSP3 induced the strongest in vivo
protection observed in this model of human malaria against a
P. falciparum challenge [74]. Although anti-MSP3 IgG3 may be
only a marker, associated with but not directly responsible for
p r o t e c t i o n ,t h e r ei sar e m a r k a b l ec o n v e r g e n c eb e t w e e n
experimental data acquired under in vitro conditions or in
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exposed human populations.
The full sequence conservation of the B cell epitopes from
the C-terminal region conﬁrms previous results [24,25] and
contrasts with the polymorphism found in other regions of
MSP3 and in other antigens, such as CS, TRAP, MSP1, and
MSP2. We have previously discussed why an indirect
mechanism such as ADCI is consistent with the phenomenon
of chronicity and why it does not lead, in contrast to direct
mechanisms of action of antibodies, to antigen polymor-
phisms [75]. In this respect it seems debatable to employ the
most polymorphic part of MSP3 for vaccine studies, as was
proposed recently [76], particularly since the conserved C
terminus has now demonstrated its ability to elicit in humans
antibodies that kill P. falciparum [71]. The C-terminal part of
MSP3 has structural homology with MSP6, and has sequence
identities (ILGWEFGGGA/VP) within the MSP3b peptide
region resulting in fully cross-reactive epitopes between the
two molecules [77]. This observation and the recent ﬁnding
that these two molecules belong to a multigene family with
structural and immunological homologies (S. Singh et al.,
unpublished data), reinforce the immunological importance
of the MSP3b epitope and make it understandable that
knocking out one of the family members has few functional
consequences [78]. Conservation of the sequence across
isolates and duplication of the sequence in other genes are
of evident importance whether MSP3 constitutes only a
surrogate marker as shown here and in previous studies
[22,23,58,69–71,79] or whether, as suggested elsewhere, it also
has vaccine potential against P. falciparum [70,71,74,80]. We
therefore hope that the present results will trigger the
implementation of more immunoepidemiological studies to
further document this important ﬁnding.
Supporting Information
Figure S1. Antibody Responses to Pre-erythrocytic Antigens among
Dielmo Inhabitants
Prevalence (% positives) to various pre-erythrocytic antigens among
217 inhabitants from Dielmo (Senegal) was measured by ELISA
against LSA1-, LSA3-, and SALSA-derived peptides, two recombinant
proteins (R32 LR and R32Tet), and a peptide (NANP4) derived from
the CS protein.
Found at doi:10.1371/journal.pmed.0040320.sg001 (6.9 MB EPS).
Figure S2. Cumulative Number of Malaria Attacks over 6 Years of
Follow-up in Dielmo in Individuals with Either High or Low Antibody
Responses to Four Leading Malaria Vaccine Candidates
For each antigen, the median value of antibody responses was
determined. Individuals with antibody responses above the median
(.median) were considered high responders (closed circles). Individ-
uals with antibody responses below the median (,median) were
considered low responders (open circles). Following a single
determination of antibodies to each antigen in blood samples, the
mean number of malaria attacks recorded in Dielmo over 6 y was
calculated for each year of the study and for each group of children
(either high or low responders to each antigen). The two subgroups
had the same mean age, so that there was no age imbalance between
children with and without malaria attacks. The mean cumulative
numbers of malaria attacks are illustrated for anti-MSP3b (A), anti-
MSP1 (B), anti-AMA1 (C) and anti-MSP2-3D7 (D) IgG3 responses.
Error bars indicate SD.
Found at doi:10.1371/journal.pmed.0040320.sg002 (1.1 MB EPS).
Table S1. Results of Univariate Analysis of Antibody Responses in
Relation to Malaria Attacks
ORs and 95% CIs were calculated to evaluate the relationship
between two binary variables (i.e., presence or absence of a positive
antibody response and occurrence or absence of malaria attack
during the 2 y of follow-up). The results are given as an indication of
effect size with ORs greater than 1 indicating that the no malaria
attack condition was more likely to happen in the group with
antibody responses speciﬁc for the antigen tested. C:NC indicates the
cytophilic to noncytophilic ratios (i.e., the ratios of [IgG1 þ IgG3]
to[IgG2 þ IgG4 þ IgM] antibody responses); NA (not available)
indicates situations where ORs could not be calculated.
Found at doi:10.1371/journal.pmed.0040320.st001 (1.2 MB EPS).
Table S2. Association between IgG3 anti-MSP3 Responses and the
Cumulative Number of Malaria Attacks over Years
A subgroup of Dielmo inhabitants present during 6 y of survey after
blood sampling was identiﬁed. Presence or absence of anti-MSP3
IgG3 responses was tested with regard to the cumulative number of
malaria attacks identiﬁed each year. The indications in favour of a
potential association between anti-MSP3 IgG3 responses and resist-
ance to malaria attacks recorded during 6 mo to 6 y following blood
sampling are given as age-adjusted ORs and 95% CIs determined for
children and adults separately.
Found at doi:10.1371/journal.pmed.0040320.st002 (482 KB EPS).
Accession Numbers
The primer positions in the MSP3seqence are based on GenBank
(http://www.ncbi.nlm.nih.gov/) accession number AF024624.
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Background. Malaria kills about one million people—mainly children—
every year. Most of these deaths are caused by Plasmodium falciparum,a
parasite transmitted to people through the bites of infected mosquitoes.
In the human body, the parasites replicate in liver cells before changing
into so-called ‘‘merozoites.’’ These infect red blood cells, where they
replicate rapidly before bursting out and infecting more red blood cells.
This massive increase in the number of parasites in the body causes a
fever and can also damage vital organs. Although individuals can protect
themselves against being bitten by mosquitoes, a vaccine is urgently
needed to reduce the global burden of malaria. Vaccines help the
immune system fight infectious diseases. When a disease-causing
organism (pathogen) enters the human body, the immune system
produces antibodies. These are proteins that recognize molecules
(antigens) on the pathogen and that enlist other parts of the immune
system to kill the invader. This process is often slow the first time around,
so people can be ill for a while. However, the immune system
‘‘remembers’’ the experience and responds much quicker to subsequent
attacks by the same pathogen. Vaccines, which contain antigens from
pathogens, prepare the immune system so that it responds quickly and
effectively to a pathogen’s first attack.
Why Was This Study Done? An effective vaccine against merozoites
would limit the severity of malaria and prevent many deaths, but
scientists do not know which of the antigens on merozoites stimulate a
protective immune response. Each candidate therefore has to be tested
in long, expensive field trials. Young children who live where malaria is
endemic (i.e., always present) have frequent attacks of malaria but
gradually develop natural immunity to the disease so that after the age
10 y, even though there are always parasites in their blood, they rarely
become ill. If researchers knew which malaria antigens and which parts
of the immune response are involved in natural immunity, they could
use this information in vaccine design. In this study, the researchers have
investigated which type of antibody (antibodies come in different
varieties or ‘‘isotypes,’’ each of which does a slightly different job in the
immune system) and which of five potential malaria antigens is
associated with protection against clinical malaria.
What Did the Researchers Do and Find? In 1990, the researchers
started a unique study in Dielmo, Senegal, West Africa, a small village
where malaria is transmission is very high all year round. For 7 y
(although the initial analysis concentrated on data from the first two
years) medical staff visited every villager daily to look for clinical signs of
malaria. Diagnoses of malaria were checked by looking for parasites in
blood samples. One year into the study, the researchers tested blood
from each participant for antibodies that recognized the candidate
malaria antigens. When they analyzed their data, they found that only
one immune response—the production of antibodies of the IgG3 isotype
directed against an antigen called merozoite surface protein 3 (MSP3)—
was strongly associated with clinical protection against malaria in all age
groups. The researchers also found that some of the children developed
protection against malaria when they were very young. Furthermore, in
children, production of anti-MSP3 IgG3 in 1991 was associated with
protection against malaria for the next 6 y.
What Do These Findings Mean? These findings show that the
production of IgG3 antibodies that recognize MSP3 is strongly associated
with the development of long-lasting natural protection against malaria.
They also show that both protection and these antibodies can develop in
very young children. Malaria transmission is unusually high in Dielmo, so
these findings may not necessarily be relevant to regions where
transmission is lower. In addition, although other research has shown
that antibodies of this type can kill parasites in test tubes and in animals,
it is possible that these antibodies are markers of, rather than causes of,
protective immunity against malaria. Nevertheless, these findings
support the continued development of MSP3-based vaccines, partic-
ularly since they suggest that early vaccination has the potential to
protect infants against life-threatening attacks of malaria.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040320.
  The MedlinePlus encyclopedia contains pages on malaria and on
vaccination (in English and Spanish)
  Information is available from the World Health Organization on malaria
(in English, Spanish, French, Russian, Arabic, and Chinese)
  The US Centers for Disease Control and Prevention provide informa-
tion on malaria and on immune responses to malaria (in English and
Spanish)
  Information is available from the Malaria Vaccine Initiative on malaria
and malaria vaccine development
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